For general inquiries, call 1 877-564-0008 or [email protected]. Fax PoNS device prescriptions to 1 (215) 754-4903.

Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®

– First patients have purchased PoNS devices to initiate PoNS Therapy –– Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch – NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the fulfillment […]

Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

– Breakthrough technology for MS patients helps patients with gait deficit – Portable Neuromodulation Stimulator (PoNS®) is an innovative non-surgical medical device that includes a controller and a mouthpiece – Available directly to patients by prescription, used in conjunction with physical therapy NEWTOWN, Pa., April 26, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq: […]

Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®

Patent Readies Company for Next Generation of PoNS Therapy NEWTOWN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,197,994, which is directed to systems […]

Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site

– Multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis –– Program to include 10-12 U.S. Centers of Excellence; enrollment to commence in Q4 2021 – NEWTOWN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the […]

Helius Medical, Inc. Receives U.S. Marketing Authorization for the PoNS™ Device

First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, […]

Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board

Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies NEWTOWN, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the formation of a Multiple Sclerosis (“MS”) Scientific Advisory Board. The Helius MS Scientific Advisory […]

Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis

NEWTOWN, Pa., May 12, 2020 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation for its PoNS™ device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (“MS”), to be used as […]

By submitting this form, you agree to receive future updates and communication regarding the PoNS® device and other Helius products, services, programs or topics of interest. Your consent is not required as a condition of receiving any goods or services from Helius. You may choose unsubscribe and choose not to receive further information from Helius by emailing [email protected]

IMPORTANT SAFETY INFORMATION

No serious adverse events related to the PoNS device were reported in the MS RCTs or in use in clinical rehabilitation settings to treat balance and gait disorders.

Some individuals have reported headaches, fatigue, and excess salivation. Excess salivation during training sessions often occurs but generally improves as patients get used to wearing the mouthpiece.

Indication
The PoNS® device is indicated for use as a short term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis and is to be used as an adjunct to a supervised therapeutic exercise program for adults 22 years of age and over by prescription only.

Contraindications
The PoNS® device delivers electrical stimulation directly to the surface of the tongue. Precautions for use are similar to those for transcutaneous electrical nerve stimulation (TENS).

Electrical stimulation should not be used:

  • If there is an active or suspected malignant tumor
  • In areas of recent bleeding or open wounds
  • In areas that lack normal sensation

The PoNS® has not been tested on, and thus should not be used by individuals who are pregnant. Do not use the PoNS® if you are sensitive to nickel, gold or copper.

Use with caution
Electrical stimulation should only be used after seeking professional medical advice, and with caution in patients with any of the following:

  • Implanted electronic devices, including:
    • Cardiac pacemakers
    • Cardioverter defibrillators
    • Deep Brain Stimulators
    • Vagal Nerve Stimulators
    • Sacral nerve stimulators
    • Cochlear Implants
  • Metal in the mouth (e.g. piercings, braces, retainers, or other orthodontic appliance)
  • Seizure disorders
  • Epilepsy

Ready to get started with PoNS?

Patients who are seeking more information on how to get PoNS can email us at [email protected], or fill out our contact form: